Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Trevisi E, Brizzi M, Espinosa Olarte P, Enguita A,

Keywords: Lung neuroendocrine tumors, tumor side (left versus right), tumor site (peripheric versus central), prognostic factors, survival,

#3031 Primitive Peripheral Neuroectodermal Tumor: Case Report

Introduction: Primitive neuroectodermal tumors belong to the family of Ewing sarcomatous tumors, all derived from the same stem cell. The cells of the neural crest are believed to be at the origin of these tumors. The predilection sites of these sarcomas are para-vertebral region, chest wall and the distal ends. The positive diagnosis of primary neuroectodermal tumors requires the contribution of histopathology, immunohistochemistry and cytogenetics.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ikram B, Soumeya G,

Keywords: Primitive neuroectodermal tumor, primary, peripheral, pPNET, CD99, surgery, chemotherapy,

#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms

Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hermans B, Derks J, Moonen L, Habraken C, von der Thusen J,

Keywords: Borderline tumor, NET grade 3, LCNEC, atypical carcinoid, WHO-classification,

#2781 Case Report: Whole Exon Sequencing of Primary Lesion and Metastatic Liver Lesion in Pancreatic Neuroendocrine Tumor

Introduction: Pancreatic neuroendocrine neoplasms(NENs) are classified into neuroendocrine tumors (NET) G1, G2, G3, and neuroendocrine carcinoma (NEC), which are different pathogenesis. The two kinds of tumors that occurs in the same lesion in one patient is very rare. We found high grade neuroendocrine neoplasms(NENG3) with a diameter of 0.1 cm in a patient with a pancreatic NETG2 (1.7 cm in diameter). The cells were significant atypia with Ki67 index of 60%, focal necrosis, while metastatic nodules in the liver (12, 0.1-1.1 cm in diameter) were all high grade NENG3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shi Y, Zhong D, Li Y, Niu Y, Tan H,

Keywords: pancreatic neuroendocrine neoplasms, whole exon sequencing, TRIOBP signaling pathway, MDM4,

#2289 Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine Neoplasia

Introduction: Targeting the death receptor pathway of apoptosis represents a promising approach for the development of novel cancer therapeutics. TNF-related TRAIL induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have been reported to block TRAIL-mediated apoptosis upon overexpression. Specially agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sättele R, Jann H, Fischer C, Pape U, Schefold J,

Keywords: TRAIL, apoptosis, NENs,